Assessment of ARVO Web-based Software for Evaluating Attention-Deficit/Hyperactive Disorder (ADHD) Symptoms in Children

Last updated: September 2, 2024
Sponsor: Peili Vision Ltd.
Overall Status: Completed

Phase

N/A

Condition

Williams Syndrome

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Treatment

Conners Continuous Performance Test 3rd Edition™ (CPT 3)

ARVO 2.0 WEB

Clinical Study ID

NCT05846815
Arvo-001
  • Ages 8-13
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Clinical investigation is aimed to assess the performance and safety of web-based ARVO 2.0, for evaluating possible Attention-Deficit/Hyperactive Disorder (ADHD) symptoms in children. Possible ADHD symptoms are recorded by using specific predetermined neurocognitive performance indicators (NPI's), derived during/from the game.

Results of ARVO are compared to the Conners Continuous Performance Test 3rd Edition™ (CPT 3) that is a task-oriented, automated 14-minute computerized assessment of attention-deficit (AD) related problems in individuals aged 8 years and older.

Performance and safety of ARVO and CPT 3 are compared in two clinical investigation populations, 8-13 years old ADHD children and typically developing (TD) children of the same age. Test are performed by the subject while monitoring adult supervises safety of the use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

ADHD group

The Inclusion criteria:

  1. Signed informed consent (by guardian and a child)

  2. Age of 8-13 at the time of consent

  3. ADHD set by a licensed physician

  4. Native language Finnish / Fluent Finnish language

TD group

The Inclusion criteria:

  1. Signed informed consent (by guardian and child)

  2. Age of 8-13 at the time of the consent

  3. Native language Finnish / Fluent Finnish language

Exclusion

Exclusion Criteria:

ADHD group

  1. Any diseases of the nervous system (ICD-10, G00-G99)

  2. Mental and behavioural disorders due to psychoactive substance use (F10-F19)

  3. Schizophrenia, schizotypal and delusional disorders (F20 - F29)

  4. Acute severe depression or mania / hypomania (F30, F32, F33)

  5. Phobic anxiety disorders, other anxiety disorders, obsessive-compulsive disorder (F40-F42)

  6. Severe mental retardation (F72)

  7. Disorders of psychological development (F80, F81, F83, F84)

  8. Medication taken for ADHD (methylphenidate, lisdexamfetamine) on the test day (24hour wash out)

  9. Atomoxetine, guanfacine

  10. Hearing or vision diagnosis (H90 Bilateral hearing loss, H53 Visual disturbances,H54 Blindness and low vision) Diagnosis search completeness criteria: Diagnosispresent/absent in patient registry Kanta.

TD group

  1. Set ADHD diagnosis.

  2. Ongoing process related to setting an ADHD diagnosis, according to guardian'squestionnaire.

  3. Any diseases of the nervous system (ICD-10, G00-G99)

  4. Mental and behavioural disorders due to psychoactive substance use (F10-F19)

  5. Schizophrenia, schizotypal and delusional disorders (F20 - F29)

  6. Acute severe depression or mania / hypomania (F30, F32, F33)

  7. Phobic anxiety disorders, other anxiety disorders, obsessive-compulsive disorder (F40-F42)

  8. Severe mental retardation (F72)

  9. Disorders of psychological development (F80, F81, F83, F84)

  10. Hearing or vision diagnosis (H90 Bilateral hearing loss, H53 Visual disturbances,H54 Blindness and low vision)

Study Design

Total Participants: 134
Treatment Group(s): 2
Primary Treatment: Conners Continuous Performance Test 3rd Edition™ (CPT 3)
Phase:
Study Start date:
November 06, 2023
Estimated Completion Date:
August 14, 2024

Connect with a study center

  • Pro Neuron Oy

    Espoo, 02650
    Finland

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.